TickerFacts.

Tarsus Pharmaceuticals, Inc. (TARS): Revenue

Annual figures by period end, from SEC filings.

$451.36M
Year ended 2025-12-31
$606.33M
Trailing 12 months to 2026-06-30
+159.5%
3-year compound annual growth
2020-12-31: $02021-12-31: $57.03M2022-12-31: $25.82M2023-12-31: $17.45M2024-12-31: $182.95M2025-12-31: $451.36M$451.36M
2020-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$451.36M+146.7%2026-02-23, From 2025-01-01
2024-12-31$182.95M+948.6%2026-02-23, From 2024-01-01
2023-12-31$17.45M-32.4%2026-02-23, From 2023-01-01
2022-12-31$25.82M-54.7%2025-02-25, From 2022-01-01
2021-12-31$57.03Mn/a2023-03-17, From 2021-01-01
2020-12-31$0n/a2022-03-14, From 2020-01-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Tarsus Pharmaceuticals, Inc. (TARS)2025-12-31$451.36M+146.7%
Immunocore Holdings plc (IMCR)2025-12-31$400.02M+29.0%
ADMA Biologics, Inc. (ADMA)2025-12-31$510.17M+19.6%
Krystal Biotech, Inc. (KRYS)2025-12-31$389.13M+33.9%
Twist Bioscience Corp (TWST)2025-09-30$376.57M+20.3%
Adaptive Biotechnologies Corp (ADPT)2025-12-31$276.98M+54.8%
Vericel Corp (VCEL)2025-12-31$276.26M+16.5%
Repligen Corp (RGEN)2025-12-31$738.26M+16.4%
Iovance Biotherapeutics, Inc. (IOVA)2025-12-31$263.50M+60.6%

Compare TARS, IMCR, ADMA, KRYS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗